Antioxidant and protective effect of hydroalcoholic extract of *Celtis australis* L. on CCl$_4$ induced hepatotoxicity

Mohammad Shokrzadeh$^{1,2}$, Hossein bakhshi jouybari$^{3,4}$, Majedeh Hosseinpour$^{4}$, Ali ziar$^{4}$, Emran Habibi$^{2,3}$

$^1$Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran  
$^2$Department of Pharmacognosy and Biotechnology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran  
$^3$Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran  
$^4$Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

**ABSTRACT**

Several human diseases including cancer, rheumatoid arthritis, and neurodegenerative and hepatic diseases are related to the destructive effect of reactive oxygen species (ROS). Antioxidants may provide a possible solution to this problem. This study was carried out to investigate the effect of hydroalcoholic extract of *Celtis australis* on CCl$_4$ induced hepatotoxicity in mice. The antioxidant activity of *C. australis* was evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay. For evaluation of hepatoprotective activity of the extract, the animals were pretreated with 200 and 400 mg/kg of *C. australis* extract intraperitoneally for 7 days and then received CCl$_4$ (0.5 ml/kg in olive oil). Liver injury was determined by serum biochemical parameters such as Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), glutathione contents of liver tissue, and histopathological studies. A significant reduction in the serum biochemical parameters was observed when compared to the CCl$_4$ receiving group. The standard antioxidant used in the study was ascorbic acid. *C. australis* extract significantly suppressed the increase in plasma activities of liver enzymes and effectively protected animals against CCl$_4$-induced hepatic tissue damages. This study confirmed the hepatoprotective effect of the hydroalcoholic extract of *C. australis*.

**Introduction**

The liver has multifunctional roles in the body like detoxification and disposition of endogenous and exogenous substances; its function may readily be damaged by viruses, hepatotoxins, and xenobiotics (solvents and drugs)(1). Oxidative damage caused by free radicals is a common mechanism of hepatotoxicity (2). Carbon tetrachloride (CCl$_4$) is an industrial solvent that is used for induction of liver toxicity in animal models. In fact, liver injury induced by CCl$_4$ depends on its metabolism by drug metabolizing enzymes located in the endoplasmic reticulum to highly reactive trichloromethyl (CCl$_3$) and trichloromethyl perox radicals (OOC(3)). These free radicals react with unsaturated fatty acids of phospholipids present in the cell membrane. Products of lipid peroxidation attack biomolecules in the liver cells, which causes cell injury (3). Antioxidant compounds reduce the action of reactive species (ROS) in damaged tissues during the recovery process and detoxify the physiological system (4). Nowadays, antioxidant agents of natural origin and medicinal plants have attracted special interest (5, 6). *Celtis australis* L. commonly called nettle tree or European hackberry (family: Cannabaceae) is an up to 25m high tree found across southern Europe and western Asia. Traditionally the plant is used in the treatment of diarrhea, dysentery, peptic ulcers, colds, amenorrhea, menorrhagia, intermenstrual bleeding and colic (7, 8). Occurrence of some flavonoids (vitexin and isovitexin), triterpenoids, and tannins was reported in this plant (9-11). In earlier reports, the methanolic leaf extract was proven to have antimicrobial (12), antioxidant, and cytotoxic effects (13). Yet systemic pharmacological studies for its use in liver diseases have not been reported. So this study was taken up to investigate the hepatoprotective activity of *C. australis* on CCl$_4$ induced hepatotoxicity in mice.

**Materials and Methods**

**Chemicals**

Carbon tetrachloride, 5,5-Dithiobis-(2- nitrobenzoic) (DTNB), glutathione (GSH), and ascorbic acid were obtained from Merck (Darmstadt, Germany). 1,1-diphenyl-2-picrylhydrazyl (DPPH) was purchased from Sigma, Chemicals Co. (St Louis, MO, USA). ALT, AST, and ALP kits were obtained from Biolabo, France. All other chemicals used were of analytical grade.

**Preparation of the extract of *C. australis* (ECA)**

The leaves of *C. australis* L. were collected from native species growing in the Caspian Hycranian forests of Hezarjarib region, Neka, Mazandaran, Iran. The plants have been identified taxonomically and authenticated by Dr. Masoud Azadbakht, assistant professor, Department of Botany, Senna University, Sari, Mazandaran, Iran.
Voucher specimens of the plants were deposited in the Herbarium of Faculty of Pharmacy, Mazandaran University of Medical Sciences, Iran (voucher no. E1-14-121).

Freshly collected leaves were shade dried and made into coarse powder. The powder was successively extracted using the maceration method with ethanol 70% (V/V) (3 times, 48 hr). Finally, the fluid extract was filtered and concentrated under reduced pressure by a rotary evaporator apparatus, dried with a freeze dryer, and stored in a well-closed pot until used for the experiments. The extraction (ECA) yield was 19.6%.

**Preliminary phytochemical screening**

The hydroalcoholic extract of *C. australis* was screened for the presence of various phytochemicals including alkaloids, sterols, triterpenoids, saponins, anthraquinone glycosides, tannins, and flavonoids (14).

**Determination of phenolic contents**

The amount of total phenol of hydroalcoholic extract of *C. australis* was determined by the Folin-Ciocalteu method. 0.1 ml of the sample solution was mixed with 0.25 ml, 1 N Folin reagent. After 5 min, 1.25 ml, 20% sodium carbonate solution was added and shaken vigorously. The absorbance of samples was measured at 725 nm after 40 min incubation at room temperature with a double beam Perkin Elmer UV/Visible spectrophotometer. A calibration curve was obtained by standard concentrations of gallic acid. The total phenolic content was expressed as equivalents of gallic acid (15).

**Determination of flavonoids contents**

The total flavonoid content was determined by the aluminum chloride method. 0.5 ml of methanolic sample solution was mixed with 1.5 ml methanol, 0.1 ml of 10% aluminum chloride in methanol, 0.1 ml of 1 M potassium acetate, and 2.8 ml of distilled water. After 30 min incubation at room temperature, the absorbance of samples was measured at 415 nm. A calibration curve was prepared by standard concentrations of aluminum chloride solution of quercetin. The total flavonoid content was expressed as equivalents of quercetin (16).

**DPPH-free radical scavenging activity**

DPPH (2,2-diphenyl-1-picrylhydrazyl) is a stable radical, which was used for determination of free radical scavenging activity of CCFE. Each dose of extract and standard sample was mixed with a methanolic solution of DPPH, then mixtures were incubated at room temperature in the dark for 30 min, and the absorbance was measured at 517 nm. Ascorbic acid was used as a standard and methanolic solution of DPPH as a negative control. Radical scavenging activity was calculated by the following formula:

\[
\frac{(A_c - A_s)}{A_c} \times 100.
\]

Where \(A_c\) and \(A_s\) are absorbance of control and sample, respectively. IC_{50} is the concentration of the sample which is required to scavenge 50% of DPPH free radical was calculated finally (17).

**Reducing ability (FRAP assay)**

The determination of total antioxidant activity was done by the FRAP assay (ferric reducing ability), with the slow modification of the Benzie and Strain method (18). The FRAP colorimetric method is based on reduction of Fe (III). Reduction of colorless ferric-tripryridyltriazine produces a blue-colored complex (ferrous-tripryridyltriazine). The working FRAP reagent was prepared daily by mixing 10 volumes of 300 mM acetate buffer (3.1 g C2H3NaO2·3H2O and 16 ml C2H4O2), pH 3.6, with 1 volume of 10 mM TPTZ (2, 4, 6-tripyridyl-s-triazine) solution in 40 mM HCl and 1 volume of 20 mM FeCl3-6H2O solution. Plant extracts (150 µl) were allowed to react with 2850 µl of the FRAP solution for 30 min at 37°C in the dark. Absorbance was measured at 593 nm. Results were expressed as μM Fe (II)/g dry mass and compared with quercetin and ascorbic acid.

**Experimental animals**

Animals were obtained from the Institute of Experimental Animal Research, Mazandaran, Iran. 8–10 week old mice weighing 20–25 g were used. All mice were maintained under standard conditions (12/12 hr light/dark cycles at room temperature) and fed rodent pellet and tap water. This study was approved by the Ethical Committee of Mazandaran University of Medical Sciences (ID: IR. MAZUMS. REC. 1394. 1441).

**Induction of liver injury**

Male mice were divided into five groups consisting of six animals in each group. Liver injury was induced in mice by intraperitoneal (i.p.) injection of CCl4 (0.5 ml/kg) dissolved in equal volume of olive oil (19). The extract treatment was started 7 days prior to CCl4 administration and continued till the end of the experiment. Animals were grouped as follows:

- **Group I**, treated with olive oil (vehicle) used as normal group.
- **Group II**, treated with single dose CCl4, i.p. (48 hr prior to sacrifice) and served as the disease control group.
- **Groups III and IV**, treated with hydroalcoholic extract of *C. australis* suspended in 0.5% Tween-80 and normal saline at doses of 200 and 400 mg/kg daily, respectively for 5 days followed by CCl4 on day 5.
- **Group V**, treated with ascorbic acid (500 mg/kg) (20) daily for 5 days followed by CCl4 on day 5.

**Assessment of hepatotoxicity**

At 48 hr after CCl4 injection all animals were anesthetized and then blood samples were collected from the carotid artery and serum was separated by centrifugation of blood at a speed of 2000 rpm for 10 min for determination of activities of various serum liver damage enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
(ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). For the estimation of ALT and AST activities in serum samples, commercially available enzymatic kits (based on the reaction of 2,4-dinitrophenylhydrazine with pyruvate and/or oxaloacetate to yield a brown-colored complex in an alkaline medium) were used. Serum ALP activity was evaluated using the spectrophotometric method. Above biochemical parameters were expressed as U/L (21, 22).

**Reduced glutathione (GSH) level**

The livers were removed immediately, washed with normal saline and a 50% homogenate prepared in 0.05 M sodium phosphate buffer (pH 7.0). The homogenate was centrifuged at 700 x g for 10 min at 4°C and the supernatant was used for the estimation of GSH. Ellman's reagent (5,5'-Dithiobis (2-nitrobenzoic acid) solution) was added to the sample. The absorbance of the sample was recorded at 417 nm and finally GSH level expressed as µmol/g (23).

**Histological analysis**

At first, the liver tissue was fixed in buffered formalin and embedded in paraffin. Then cut into thin sections of 4 µm thickness. Sections were then deparaffinized and stained with hematoxylin and eosin (H&E) for examination by a light microscope. Slides were viewed and photographed using a camera microscope (Labomed, LX400).

**Statistical analysis**

All values for biochemical parameters and in vitro antioxidant studies were expressed as mean±SEM (standard error of mean) and analyzed by one-way analysis of variance (ANOVA) and TUIKEY’s test using SPSS16 software. p<0.05 was considered significant. All measurements were replicated 3 times.

**Results**

The preliminary phytochemical screening of hydroalcoholic extract of *C. australis* leaves revealed the presence of flavonoids, triterpenoids, saponins, sterols, tannins, loss of anthraquinone glycosides, and alkaloids.

**Total phenolic and flavonoid content**

Total phenolic and flavonoid content of hydroalcoholic extract of *C. australis* leaves were expressed as mg of gallic acid and quercetin/ g dry extract, and determined from the standard curves with the equations below respectively:

\[(y=0.006x+0.039, r^2=0.996)\] and \[(y=0.1106x, r^2=0.993)\], respectively. The hydroalcoholic extract exhibited high phenol with concentration resulted 109.4 mg gallic acid/g dry extract) and flavonoid (8.2 mg quercetin/g dry extract) content.

**Antioxidant properties**

The DPPH radical scavenging activity of hydroalcoholic extract of *C. australis* was measured by the spectrophotometric method and the IC\(_{50}\) value was calculated using the regression line equation and compared with the standard (ascorbic acid). The mean IC\(_{50}\) value of ascorbic acid was 14.3 ± 1.08 µg/ml and the mean IC\(_{50}\) value of hydroalcoholic extract of *C. australis* was 80.5 ± 1.73 µg/ml. The reducing ability and antioxidant potentials of the methanol extracts of the leaves of *C. australis* were estimated from their ability to reduce the TPTZ-Fe (III) complex to TPTZ-Fe (II) and 595.98 µm Fe (II)/g. The FRAP values for the methanol extracts of the leaves of *C. australis* were significantly lower than those of ascorbic acid (1382.98 µm Fe (II)/g) and quercetin (895.98 µm Fe (II)/g).

**Effects of extracts on AST, ALT, ALP, and GSH**

The data outlined in Table 1, shows that all biochemical parameters (serum ALT, AST, and ALP activities) were raised significantly (P < 0.001) in CCl\(_4\) alone receiving animals compared to the Olive oil (control) group, which indicates acute hepatocellular damage. Also, groups that received ECA (200 mg/kg and 400 mg/kg) followed by CCl\(_4\) injection, and the group that received ascorbic acid (500 mg/kg) then CCl\(_4\) showed significant decrease (P < 0.001) in all serum enzymes compared to the CCl\(_4\) alone group. In this study, effects of CCl\(_4\) on the liver tissue when compared with normal revealed a significant decrease (P < 0.001) in the reduced glutathione activity. Also, the maximum effect was observed after 5 days pretreatment with 400 mg/kg ECA, when GSH content in liver tissues was significantly (P < 0.001) higher (107.01±5.51 µmol/g) than those of the CCl\(_4\) alone treated mice (Table 1). The data clearly show that pretreatment with ECA resulted in significant (P<0.001) dose-dependent alterations of the biochemical parameter levels induced by CCl\(_4\) as reported in Table 1.

**Histopathological observations**

Results of histopathological studies provided supportive evidence for biochemical analysis. The liver section of the normal animals exhibited normal cellular architecture with actual cytoplasm, prominent nucleus, distinct central vein, and hepatic lobules without any fatty changes or necrosis (Figure 1A). Histology of liver section of CCl\(_4\) treated mice determined hepatic cells with serious toxicity defined by thorough loss of hepatic architecture with intense peripheral and central vein necrosis, apoptosis, vacuolization of cytoplasm, centrilobular fatty degeneration and congestion of hepatocyte sinusoids (Figure 1B). Histological section of the liver treated with standard ascorbic acid exhibited normal architecture without any fatty changes as shown in Figure 1C. Treatment with a low dose of methanolic extract (200 mg/kg) displayed swelling of hepatocyte, hepatocyte atrophy, degeneration of hepatocytes, proliferation of Kupffer cells, and mild fatty changes with central vein damage (Figure 1D) whereas high dose of methanolic extracts of *C. australis* showed normal...

**Table 1** Effect of hydroalcoholic extract of *C. australis* on mice serum enzymes and GSH of the liver after CCl₄ administration.

<table>
<thead>
<tr>
<th>Groups/Parameter</th>
<th>ALT (U/L)</th>
<th>AST (U/L)</th>
<th>ALP (U/L)</th>
<th>GSH (µmol/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>olive oil (control)</td>
<td>61.00±0.58***</td>
<td>117.00±1.15***</td>
<td>146.08±2.08***</td>
<td>137.34±3.18***</td>
</tr>
<tr>
<td>only CCl₄</td>
<td>78.33±2.33***</td>
<td>152.33±1.21***</td>
<td>199.67±1.45***</td>
<td>59.67±4.06***</td>
</tr>
<tr>
<td>ECA 200 mg/kg+CCl₄</td>
<td>70.34±0.88***###</td>
<td>139.67±0.88###</td>
<td>175.34±2.73###</td>
<td>78.00±1.53###</td>
</tr>
<tr>
<td>ECA 400 mg/kg+CCl₄</td>
<td>68.66±1.21***</td>
<td>132.34±1.45###</td>
<td>166.33±1.68###</td>
<td>107.01±5.51### ***</td>
</tr>
<tr>
<td>ascorbic acid 500 mg/kg+CCl₄</td>
<td>64.00±0.57***</td>
<td>123.00±1.15***</td>
<td>150.68±2.96***</td>
<td>121.34±3.18***</td>
</tr>
</tbody>
</table>

*Values are the mean ± S.E, n = 6, *** Significance P ≤ 0.001 compared to CCl₄ control, ### Significance P ≤ 0.001 compared to Olive oil control.*

**Figure 1** (A): Liver sections of normal control mice exhibiting normal hepatic cells with well-preserved cytoplasm, prominent nucleus, normal central vein and lobules without any fatty damages or necrosis. (B): Liver section of mice treated with CCl₄ showing hepatic cells with serious toxicity defined by thorough loss of hepatic architecture and intense peripheral and central vein necrosis, apoptosis, vacuolization of cytoplasm, centrilobular fatty degeneration, and congestion of hepatocyte sinusoids. (C): Histological liver sections of mice treated with standard ascorbic acid showing normal cells without any fatty changes. (D): Treatment with a low dose of methanolic extract (200 mg/kg) displaying swelling of hepatocytes, hepatocyte atrophy, degeneration of hepatocytes, proliferation of Kupffer cells, and mild fatty changes with central vein damage. (E): High dose of methanolic extracts of *C. australis* showing normal hepatic architecture only with a moderate accumulation of fatty lobules.

hepatic architecture only with moderate accumulation of fatty lobules (Figure 1E).

**Discussion**

Liver toxicity is a prevalent disorder resulting in serious weakness ranging from severe metabolic disease to some fatal illnesses. It is a serious challenge to global public health. In modern medical practice, liver-protective drugs are insufficient and sometimes cause serious health problems. Therefore, nowadays herbal remedies have gained much consideration for treating liver diseases due to fewer side effects and more
effectiveness (24). Many of the medicinal plants were examined for their potential antioxidant and protective effects in liver damaged experimental animal models and revealed that hepatoprotective effect of these plants may be related to the existence of various compounds such as polyphenols, flavonoids, terpenoids, coumarins, alkaloids, and phytosterols, which act as antioxidants and free radical scavengers (25). Indeed natural product roles in oxidative stress have two aspects: enhancing the activity of original natural antioxidants like GSH and neutralizing reactive oxygen species by nonenzymatic mechanisms (26). So, with this objective, C. australis L. like other species of this genus was investigated for its useful role against experimentally induced liver injury in mice due to the presence of high total phenols, flavonoids, triterpenoids, saponins, sterols, and tannins (27, 28). Liver damages are related to oxidative stress. Exposure of hepatocytes to CCl4 leads to central venous necrosis and steatosis due to the predominant formation of CCl3 and CH2Cl free radicals, which results in lipid peroxidation and cell destruction (29). In this study, liver damage induced by CCl4 in mice was determined based on significant raises in ALT, AST, and ALP, which resulted from cell membrane and mitochondrial damage in liver cells and also histopathological observations that are similar to the earlier studies (30, 31). One of the most important factors in a plant for protecting the liver is the ability of its chemical compounds and secondary metabolites to inhibit the aromatase activity of cytochrome P-450, favoring the regeneration of the liver. Therefore, it is suggested that flavonoids in C. australis could be a factor facilitating its liver-protective action via inhibition of cytochrome P-450 aromatase (32).

Also, previous studies suggest that antioxidative compounds like phenols and flavonoids may have a protective effect against hepatocyte toxicity by inhibition of lipid peroxidation and protection of glutathione depletion (33, 34). Some flavonoid C-glycosides have been reported from leaves of the Celtis species. Isovitenin, 2"-a-L-rhamnopyranosyl-7-O-methylvitexin, cytisoside, and 2"-a-L-rhamnopyranosylvitexin were isolated from C. australis L. Rich flavone C-glycosides extracts of some plants and isolated flavone C-glycosides showed significant antioxidant and hepatoprotective activity (35).

In this study, ascorbic acid was used as a standard liver-protective agent. Upon treatment with ascorbic acid, all increased biochemical parameters by CCl4 were reversed back to normal. Earlier findings indicate that ascorbic acid shows appropriate hepatoprotective and antioxidant potential against hepatocellular damage in experimental animal models (36, 37). Administration of C. australis extract in high and low dose to mice caused a decrease in the activity of the biochemical parameters of the liver, which may be a result of the stabilization of the cell membrane as well as modification of hepatic tissue damage induced by CCl4. It is believed that serum levels of transaminases are normalized with healed parenchyma and regeneration of hepatocytes (38). In this study, pre-treatment of animals with C. australis extracts exhibited an amelioration in liver enzymes, and their tendency to return towards a near normal level proposed that the plant was a suitable hepatoprotectant. Observations and histopathological changes in the liver sections of different treatment groups support this finding.

The results of the present study suggest that hydroalcoholic extract of C. australis has hepatoprotective activity that is related to glutathione-mediated detoxification as well as free radical scavenging (antioxidant activity). Its membrane stabilizing effect on hepatic cells may be connected with its phenols, flavonoids, alkaloids, and tannins content. Further study on the leaves of C. australis could be undertaken for the isolation and purification of active components.

Conflicts of interest
Authors declare no conflicts of interest.

References

Pharm Biomed Res 2018; 4(3): 30

Pharm Biomed Res 2018; 4(3): 31